Skip to content
You are now leaving to visit


ION455, also known as AZD7503, is an investigational antisense medicine designed for the treatment of nonalcoholic steatohepatitis (NASH).

About Nonalcoholic Steatohepatis (NASH)
Non-alcoholic fatty liver disease (NAFLD) describes the full spectrum of liver disease progression from fatty liver to non-alcoholic steatohepatitis (NASH) to cirrhosis to hepatocellular carcinoma. While fatty liver is often asymptomatic, NASH, which is characterized by liver steatosis, inflammation, and scarring, can lead to increased risk of cardiovascular disease, need for liver transplantation, and early death. NASH epidemiology studies have estimated 13-32% of the global population has NAFLD, 1.5%-6.5% have NASH, and approximately 9% of NASH patients progress to advanced liver disease. There are currently no commercially available NASH medications.

Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.